Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Research and Markets: Rheumatology Thought Leader Panel - Lupus/Rheumatoid Arthritis - 2012

Research and Markets
Posted on: 12 Oct 12

Research and Markets (http://www.researchandmarkets.com/research/qbr8hn/rheumatology) has announced the addition of the "Rheumatology Thought Leader Panel #36 2012-08 Lupus / Rheumatoid Arthritis" report to their offering.

Rheumatology Thought Leader Panel #36 2012-08 captures discussions with 6 internationally recognized experts (4 US, 2 EU) in the treatment of lupus

and rheumatoid arthritis. The two main topics this Panel was asked to address were:

1) What are the most significant therapies in the lupus pipeline?

2) What toxicologies are going to limit the use of oral DMARDs for rheumatoid arthritis?

Lupus nephritis is to rheumatology today what rheumatoid arthritis was in the early 90's. For those too young to remember, most pharmaceutical companies obsessed with the need to commercialize a disease modifying therapy for osteoarthritis; because the patient population, and thus the commercial opportunity, was so much larger than rheumatoid arthritis. Clinically relevant druggable targets for osteoarthritis have been devilishly hard to develop. But the few pharma companies that instead focused on attacking the underlying autoimmune mechanisms produced highly successful franchises that now branch across rheumatoid arthritis, Crohn's/ulcerative colitis, psoriasis, psoriatic arthritis, ankylosing spondylitis and more. While mild-to-moderate systemic lupus erythematosus is easy to treat, lupus nephritis is associated with high morbidity and mortality. Today osteoarthritis is routinely

and effectively treated with hip, knee and shoulder replacement. Second only to nonsurgical reversal of osteoarthritis, a pharmacotherapy for lupus nephritis is the largest unmet need in the rheumatology space. This is the topic for the first half of Rheum TLP #36.

Key Topics Covered:

Executive Summary

Introduction

Report Highlights

- Lupus Discussion

-- Unmet Needs / Diagnosis / Biomarkers

-- BAFF

--- Benlysta (belimumab; HGS / GSK)

--- blisibimod Anthera

--- tabalumab (LY2127399; Lilly)

--- atacicept (Merck-Serono)

-- CTLA4 Agonist

--- Orencia (abatacept / ONO-4164SC / BMS-188667SC; BMS / Ono)

-- CD20

--- Rituxan / MabThera (rituximab; Roche / Biogen)

--- rituximab biosimilars (manufacturers: Celltrion, Teva, Sandoz, Spectrum/Viropro, Pfizer, Merck, Vifor, Dr. Reddy) p47

-- CD22

--- epratuzumab (UCB / Immunomedics)

-- anti-IFN p53

--- sifalimumab MEDI-545 anti-IFN / MedImmune / AstraZeneca

--- rontalizumab rhuMAb IFN / (Genentech)

--- IFN-K (Neovacs)

--- AMG-811 anti-IFN

-- RNP

--- Lupuzor (ImmuPharma)

-- IL6

--- tocilizumab (Roche / Chugai)

-- immunomodulatory

--- laquinimod (Teva)

- Rheumatoid Arthritis / Psoriatic Arthritis Discussion

-- JAK

--- tofacitinib (Pfizer)

--- VX-509 (Vertex)

--- GLPG0634 Galapagos / Abbott

--- baricitinib LY3009104 (INCB28050; Incyte / Lilly)

--- ASP015K (Astellas)

-- Syk

--- fostamatinib (AstraZeneca / Rigel)

--- PRT-062607 (Portola / Biogen)

--- GS-9973 (Gilead)

--- GSK-143 (GlaxoSmithKline)

-- CCR1 / IP10 / CXCR3

--- CCX354-C (GSK / ChemoCentryx)

--- SCH-546738 (Merck)

--- PS372424 (Newcastle)

--- Boehringer-Ingelheim

-- BTK

--- ibrutinib (PCI-32765; Janssen / Pharmacyclics)

--- RN486 (Roche)

--- GDC-0834 (Roche / Genentech / Biogen)

--- AVL-292 (Celgene /Avila)

-- ONO-WG-307 (Ono)

--- TP-0829 (Tolero / MannKind)

-- PDE4

--- apremilast (Celgene)

-- Cathepsin K

--- odanacatib (Merck)

Thought Leader Interviews

Companies Mentioned

- Amgen

- Anthera

- Astellas

- AstraZeneca / Medimmune

- AstraZeneca / Rigel

- Boehringer-Ingelheim

- Bristol-Myers Squibb / Ono

- Celgene

- Celgene /Avila

- Celltrion

- Dr. Reddy

- Galapagos / Abbott

- Gilead

- GSK / ChemoCentryx

- GSK / HGS belimumab Benlysta

- ImmuPharma

- Incyte / Lilly

- Lilly

- Merck

- Merck-Serono

- Neovacs

- Newcastle

- Novartis (Sandoz)

- Ono

- Pfizer

- Pharmacyclics / Janssen

- Portola / Biogen

- Rigel / AstraZeneca

- Roche / Genentech / Chugai

- Roche / Genentech / Biogen

- Spectrum/ Viropro

- Teva

- Tolero / MannKind

- UCB / Immunomedics

- Vertex

- Vifor

For more information visit http://www.researchandmarkets.com/research/qbr8hn/rheumatology

Business Wire
http://www.businesswire.com/

Last updated on: 12/10/2012

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.